Transplantation of human neural stem cells in a parkinsonian model exerts neuroprotection via regulation of the host microenvironment

International Journal of Molecular Sciences

Volumn 16, Issue 11, 2015, Pages 26473-26492

  Zuo, Fu Xing ^a   Bao, Xin Jie ^a   Sun, Xi Cai ^b   Wu, Jun ^b   Bai, Qing Ran ^b   Chen, Guo ^b   Li, Xue Yuan ^a   Zhou, Qiang Yi ^a   Yang, Yuan Fan ^a   Shen, Qin ^b   Wang, Ren Zhi ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

Endogenous de differentiated astrocytes; Neural stem cells; Niche; Parkinson s disease; Transplantation

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH FACTOR; KI 67 ANTIGEN; AUTACOID; DOPAMINE; NERVE GROWTH FACTOR;

ADULT; ANIMAL BEHAVIOR; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HISTOLOGY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MICROGLIA; MOUSE; NEURAL STEM CELL TRANSPLANTATION; NEUROPROTECTION; NONHUMAN; PARKINSONISM; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; ANIMAL; CELL DIFFERENTIATION; CELL LINE; CELL MOTION; CELL SURVIVAL; CORPUS STRIATUM; CYTOLOGY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; HUMAN; METABOLISM; NEURAL STEM CELL; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; STEM CELL TRANSPLANTATION; TUMOR MICROENVIRONMENT;

ANIMALS; ASTROCYTES; CELL DIFFERENTIATION; CELL LINE; CELL MOVEMENT; CELL SURVIVAL; CELLULAR MICROENVIRONMENT; CORPUS STRIATUM; CYTOKINES; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; HUMANS; INFLAMMATION MEDIATORS; MICE; MICROGLIA; NERVE GROWTH FACTORS; NEURAL STEM CELLS; NEUROPROTECTION; PARKINSON DISEASE; PHENOTYPE; STEM CELL TRANSPLANTATION;

EID: 84946605571     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161125966     Document Type: Article

References (50)

1. Dauer, W.; Przedborski, S. Parkinson’s disease: Mechanisms and models. Neuron 2003, 39, 889–909. [CrossRef]
2. Hung, A.Y.; Schwarzschild, M.A. Treatment of Parkinson’s disease: What’s in the non-dopaminergic pipeline? J. Am. Soc. Exp. Neurother. 2014, 11, 34–46. [CrossRef] [PubMed]
3. Arenas, E. Towards stem cell replacement therapies for Parkinson’s disease. Biochem. Biophys. Res. Commun. 2010, 396, 152–156. [CrossRef] [PubMed]
4. Gage, F.H. Neurogenesis in the adult brain. J. Neurosci. 2002, 22, 612–613. [PubMed]
5. Ming, G.L.; Song, H. Adult neurogenesis in the mammalian central nervous system. Annu. Rev. Neurosci. 2005, 28, 223–250. [CrossRef] [PubMed]
6. Madhavan, L.; Daley, B.F.; Sortwell, C.E.; Collier, T.J. Endogenous neural precursors influence grafted neural stem cells and contribute to neuroprotection in the parkinsonian rat. Eur. J. Neurosci. 2012, 35, 883–895. [CrossRef] [PubMed]
7. Ourednik, J.; Ourednik, V.; Lynch, W.P.; Schachner, M.; Snyder, E.Y. Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons. Nat. Biotechnol. 2002, 20, 1103–1110. [CrossRef] [PubMed]
8. Yasuhara, T.; Matsukawa, N.; Hara, K.; Yu, G.; Xu, L.; Maki, M.; Kim, S.U.; Borlongan, C.V. Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson’s disease. J. Neurosci. 2006, 26, 12497–12511. [CrossRef] [PubMed]
9. Li, X.Y.; Bao, X.J.; Wang, R.Z. Potential of neural stem cell-based therapies for Alzheimer’s disease. J. Neurosci. Res. 2015, 93, 1313–1324. [CrossRef] [PubMed]
10. Jiao, J.; Chen, D.F. Induction of neurogenesis in nonconventional neurogenic regions of the adult central nervous system by niche astrocyte-produced signals. Stem Cells 2008, 26, 1221–1230. [CrossRef] [PubMed]
11. Harrower, T.P.; Tyers, P.; Hooks, Y.; Barker, R.A. Long-term survival and integration of porcine expanded neural precursor cell grafts in a rat model of Parkinson’s disease. Exp. Neurol. 2006, 197, 56–69. [CrossRef] [PubMed]
12. Inyushin, M.Y.; Huertas, A.; Kucheryavykh, Y.V.; Kucheryavykh, L.Y.; Tsydzik, V.; Sanabria, P.; Eaton, M.J.; Skatchkov, S.N.; Rojas, L.V.; Wessinger, W.D. L-DOPA uptake in astrocytic endfeet enwrapping blood vessels in rat brain. Parkinson’s Dis. 2012, 2012. [CrossRef] [PubMed]
13. Simard, M.; Arcuino, G.; Takano, T.; Liu, Q.S.; Nedergaard, M. Signaling at the gliovascular interface. J. Neurosci. 2003, 23, 9254–9262. [PubMed]
14. Lois, C.; Garcia-Verdugo, J.M.; Alvarez-Buylla, A. Chain migration of neuronal precursors. Science 1996, 271, 978–981. [CrossRef] [PubMed]
15. Lin, R.C.; Matesic, D.F.; Marvin, M.; McKay, R.D.; Brüstle, O. Re-expression of the intermediate filament nestin in reactive astrocytes. Neurobiol. Dis. 1995, 2, 79–85. [CrossRef] [PubMed]
16. Wachter, B.; Schurger, S.; Rolinger, J.; von Ameln-Mayerhofer, A.; Berg, D.; Wagner, H.J.; Kueppers, E. Effect of 6-hydroxydopamine (6-OHDA) on proliferation of glial cells in the rat cortex and striatum: Evidence for de-differentiation of resident astrocytes. Cell Tissue Res. 2010, 342, 147–160. [CrossRef] [PubMed]
17. Gomide, V.C.; Silveira, G.A.; Chadi, G. Transient and widespread astroglial activation in the brain after a striatal 6-OHDA-induced partial lesion of the nigrostriatal system. Int. J. Neurosci. 2005, 115, 99–117.[CrossRef] [PubMed]
18. Niu, W.; Zang, T.; Zou, Y.; Fang, S.; Smith, D.K.; Bachoo, R.; Zhang, C.L. In vivo reprogramming of astrocytes to neuroblasts in the adult brain. Nat. Cell Biol. 2013, 15, 1164–1175. [CrossRef] [PubMed]
19. Guo, Z.; Zhang, L.; Wu, Z.; Chen, Y.; Wang, F.; Chen, G. In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer’s disease model. Cell Stem Cell 2014, 14, 188–202. [CrossRef] [PubMed]
20. Seyedzadeh, M.H.; Safari, Z.; Zare, A.; Gholizadeh Navashenaq, J.; Razavi, S.A.; Kardar, G.A.; Khorramizadeh, M.R. Study of curcumin immunomodulatory effects on reactive astrocyte cell function. Int. Immunopharmacol. 2014, 22, 230–235. [CrossRef] [PubMed]
21. Chen, Y.; Zhang, J.; Deng, M. Furin mediates brain-derived neurotrophic factor upregulation in cultured rat astrocytes exposed to oxygen-glucose deprivation. J. Neurosci. Res. 2015, 93, 189–194. [CrossRef] [PubMed]
22. Akerud, P.; Canals, J.M.; Snyder, E.Y.; Arenas, E. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson’s disease. J. Neurosci. 2001, 21, 8108–8118. [PubMed]
23. Niranjan, R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson’s disease: Focus on astrocytes. Mol. Neurobiol. 2014, 49, 28–38. [CrossRef] [PubMed]
24. Park, D.H.; Eve, D.J.; Musso, J., 3rd; Klasko, S.K.; Cruz, E.; Borlongan, C.V.; Sanberg, P.R. Inflammation and stem cell migration to the injured brain in higher organisms. Stem Cells Dev. 2009, 18, 693–702. [CrossRef] [PubMed]
25. Burnstein, R.M.; Foltynie, T.; He, X.; Menon, D.K.; Svendsen, C.N.; Caldwell, M.A. Differentiation and migration of long term expanded human neural progenitors in a partial lesion model of Parkinson’s disease. Int. J. Biochem. Cell Biol. 2004, 36, 702–713. [CrossRef] [PubMed]
26. Liker, M.A.; Petzinger, G.M.; Nixon, K.; McNeill, T.; Jakowec, M.W. Human neural stem cell transplantation in the MPTP-lesioned mouse. Brain Res. 2003, 971, 168–177. [CrossRef]
27. Jackson-Lewis, V.; Przedborski, S. Protocol for the MPTP mouse model of Parkinson’s disease. Nat. Protoc. 2007, 2, 141–151. [CrossRef] [PubMed]
28. Mason, H.A.; Ito, S.; Corfas, G. Extracellular signals that regulate the tangential migration of olfactory bulb neuronal precursors: Inducers, inhibitors, and repellents. J. Neurosci. 2001, 21, 7654–7663. [PubMed]
29. Uchida, N.; Buck, D.W.; He, D.; Reitsma, M.J.; Masek, M.; Phan, T.V.; Tsukamoto, A.S.; Gage, F.H.; Weissman, I.L. Direct isolation of human central nervous system stem cells. Proc. Natl. Acad. Sci. USA 2000, 97, 14720–14725. [CrossRef] [PubMed]
30. Tansey, M.G.; Goldberg, M.S. Neuroinflammation in Parkinson’s disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 2010, 37, 510–518. [CrossRef] [PubMed]
31. Marchetti, B.; Abbracchio, M.P. To be or not to be (inflamed)—Is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? Trends Pharmacol. Sci. 2005, 26, 517–525. [CrossRef] [PubMed]
32. Madhavan, L.; Daley, B.F.; Paumier, K.L.; Collier, T.J. Transplantation of subventricular zone neural precursors induces an endogenous precursor cell response in a rat model of Parkinson’s disease. J. Comp. Neurol. 2009, 515, 102–115. [CrossRef] [PubMed]
33. Panickar, K.S.; Norenberg, M.D. Astrocytes in cerebral ischemic injury: Morphological and general considerations. Glia 2005, 50, 287–298. [CrossRef] [PubMed]
34. Hu, X.; Zhang, D.; Pang, H.; Caudle, W.M.; Li, Y.; Gao, H.; Liu, Y.; Qian, L.; Wilson, B.; di Monte, D.A.; et al. Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. J. Immunol. 2008, 181, 7194–7204. [CrossRef] [PubMed]
35. Yokoyama, H.; Uchida, H.; Kuroiwa, H.; Kasahara, J.; Araki, T. Role of glial cells in neurotoxin-induced animal models of Parkinson’s disease. Neurol. Sci. 2011, 32, 7. [CrossRef] [PubMed]
36. Episcopo, F.L.; Tirolo, C.; Testa, N.; Caniglia, S.; Morale, M.C.; Marchetti, B. Reactive astrocytes are key players in nigrostriatal dopaminergic neurorepair in the MPTP mouse model of Parkinson’s disease: Focus on endogenous neurorestoration. Curr. Aging Sci. 2013, 6, 45–55. [CrossRef]
37. Aoki, E.; Yano, R.; Yokoyama, H.; Kato, H.; Araki, T. Role of nuclear transcription factor kappa B (NF-_B) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice. Exp. Mol. Pathol. 2009, 86, 57–64. [CrossRef] [PubMed]
38. Schneider, J.S.; Denaro, F.J. Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain. J. Neuropathol. Exp. Neurol. 1988, 47, 452–458. [CrossRef] [PubMed]
39. Chadi, G.; Gomide, V.C. FGF-2 and S100_ immunoreactivities increase in reactive astrocytes, but not in microglia, in ascending dopamine pathways following a striatal 6-OHDA-induced partial lesion of the nigrostriatal system. Cell Biol. Int. 2004, 28, 849–861. [CrossRef] [PubMed]
40. Kang, P.J.; Moon, J.H.; Yoon, B.S.; Hyeon, S.; Jun, E.K.; Park, G.; Yun, W.; Park, J.; Park, M.; Kim, A.; et al. Reprogramming of mouse somatic cells into pluripotent stem-like cells using a combination of small molecules. Biomaterials 2014, 35, 7336–7345. [CrossRef] [PubMed]
41. Nakajima, K.; Hida, H.; Shimano, Y.; Fujimoto, I.; Hashitani, T.; Kumazaki, M.; Sakurai, T.; Nishino, H. GDNF is a major component of trophic activity in DA-depleted striatum for survival and neurite extension of DAergic neurons. Brain Res. 2001, 916, 76–84. [CrossRef]
42. Niles, L.P.; Armstrong, K.J.; Rincón Castro, L.M.; Dao, C.V.; Sharma, R.; McMillan, C.R.; Doering, L.C.; Kirkham, D.L. Neural stem cells express melatonin receptors and neurotrophic factors: Colocalization of the MT1 receptor with neuronal and glial markers. BMC Neurosci. 2004, 5. [CrossRef] [PubMed]
43. Delgado, A.C.; Ferron, S.R.; Vicente, D.; Porlan, E.; Perez-Villalba, A.; Trujillo, C.M.; D'Ocón, P.; Fariñas, I. Endothelial NT-3 delivered by vasculature and CSF promotes quiescence of subependymal neural stem cells through nitric oxide induction. Neuron 2014, 83, 572–585. [CrossRef] [PubMed]
44. Kordower, J.H.; Emborg, M.E.; Bloch, J.; Ma, S.Y.; Chu, Y.; Leventhal, L.; McBride, J.; Chen, E.Y.; Palfi, S.; Roitberg, B.Z.; et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science 2000, 290, 767–773. [CrossRef] [PubMed]
45. Iravani, M.M.; Sadeghian, M.; Leung, C.C.; Jenner, P.; Rose, S. Lipopolysaccharide-induced nigral inflammation leads to increased IL-1_ tissue content and expression of astrocytic glial cell line-derived neurotrophic factor. Neurosci. Lett. 2012, 510, 138–142. [CrossRef] [PubMed]
46. Redmond, D.E.; Bjugstad, K.B.; Teng, Y.D.; Ourednik, V.; Ourednik, J.; Wakeman, D.R.; Parsons, X.H.; Gonzalez, R.; Blanchard, B.C.; Kim, S.U.; et al. Behavioral improvement in a primate Parkinson’s model is associated with multiple homeostatic effects of human neural stem cells. Proc. Natl. Acad. Sci. USA 2007, 104, 12175–12180. [CrossRef] [PubMed]
47. Sun, X.; Zhang, Q.W.; Xu, M.; Guo, J.J.; Shen, S.W.; Wang, Y.Q.; Sun, F.Y. New striatal neurons form projections to substantia nigra in adult rat brain after stroke. Neurobiol Dis. 2012, 45, 601–609. [CrossRef] [PubMed]
48. Herzog, C.D.; Dass, B.; Gasmi, M.; Bakay, R.; Stansell, J.E.; Tuszynski, M.; Bankiewicz, K.; Chen, E.Y.; Chu, Y.; Bishop, K.; et al. Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol. Ther. 2008, 16, 1737–1744. [CrossRef] [PubMed]
49. Belmadani, A.; Tran, P.B.; Ren, D.; Miller, R.J. Chemokines regulate the migration of neural progenitors to sites of neuroinflammation. J. Neurosci. 2006, 26, 3182–3191. [CrossRef] [PubMed]
50. Chen, X.; Burdett, T.C.; Desjardins, C.A.; Logan, R.; Cipriani, S.; Xu, Y.; Schwarzschild, M.A. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc. Natl. Acad. Sci. USA 2013, 110, 300–305. [CrossRef] [PubMed]